Sector News

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

October 1, 2023
Life sciences

Medtech companies are studying a range of catheter-directed treatments for pulmonary embolism, a condition defined by blood clots in the lung. Boston Scientific’s EkoSonic uses ultrasound to dissolve PEs, while Inari’s FlowTriever captures and removes clots. Physicians continue to debate when to use each device.

“There is still a lack of consensus on what is the right device to use and on which patient, given difficulties risk-stratifying patients and the lack of Level I evidence. A panelist discussed how choosing a device is more nuanced and often dependent on user preference, experience and type of clot (proximal vs. distal). We think this could potentially change as new RCT data emerges,” the BTIG analysts wrote.

The analysts shared details of a debate between key opinion leaders to illustrate the lack of consensus. Three experts discussed which catheter to use on an 80-year-old PE patient. One person cited data from Boston Scientific clinical trials to argue for catheter-directed thrombolysis. Another expert used the hemodynamic response and safety profile seen in an Inari study to make the case for aspiration thrombectomy. The third expert proposed a mix of mechanical thrombectomy and catheter-directed thrombolysis. READ MORE

By Nick Paul Taylor

Source: medtechdive.com

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach